Ambrosia Biosciences develops orally bioavailable small molecules targeting metabolic G-protein coupled receptors, including GLP-1, GIP and amylin. The company combines structural biology with advanced computational chemistry to design molecules with differentiated pharmacology intended for both standalone therapies and strategic combinations. Its lead program is an oral small molecule GLP-1 candidate that the company intends to advance into a Phase 1 clinical trial. The recent $100 million Series B committed capital is intended to fund Ambrosia through clinical trial initiation and to support continued development of its broader small-molecule pipeline. The company is based in Boulder, Colorado, and announced a board appointment tied to the financing.

Total raised

$141M

Funding rounds

3

Latest round

Series B

Latest activity

Mar 2026